| Literature DB >> 20470443 |
Inge H F Reininga1, Wiebren Zijlstra, Robert Wagenmakers, Alexander L Boerboom, Bregtje P Huijbers, Johan W Groothoff, Sjoerd K Bulstra, Martin Stevens.
Abstract
BACKGROUND: Both minimally invasive surgery (MIS) and computer-assisted surgery (CAS) for total hip arthroplasty (THA) have gained popularity in recent years. We conducted a qualitative and systematic review to assess the effectiveness of MIS, CAS and computer-assisted MIS for THA.Entities:
Mesh:
Year: 2010 PMID: 20470443 PMCID: PMC2879237 DOI: 10.1186/1471-2474-11-92
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Methodological quality criteria list
| Item | Description |
|---|---|
| 1 | Was the method of randomization adequate? |
| 2 | Was the treatment allocation concealed? |
| 3 | Were the groups similar at baseline regarding the most important prognostic indicators? |
| 4 | Was the outcome assessor blinded to the intervention? |
| 5 | Were co-interventions avoided or similar? |
| 6 | Was the drop-out rate described and acceptable? |
| 7 | Was the timing of the outcome assessment similar in all groups? |
| 8 | Did the analysis include an intention-to-treat analysis? |
Best-evidence synthesis
| Strong evidence | Consistent findings among multiple high-quality trials* |
| Moderate evidence | Consistent findings in multiple low-quality trials and/or one high-quality trial |
| Limited evidence | Consistent findings in at least one low-quality trial |
| Conflicting evidence | Inconsistent findings among multiple trials (high- and/or low-quality trials) |
| No evidence | Findings of eligible trials do not meet the criteria for one of the levels of evidence stated above, or there are no eligible trials available |
* Consistent findings were defined as ≥75% of the trials showing results in the same direction.
Figure 1Flow chart of inclusion procedure. * Multiple reasons for excluding were possible per study. RCT = randomized controlled trial; CCT = controlled clinical trial; MIS THA = minimally invasive total hip arthroplasty; CAS THA = computer-assisted total hip arthroplasty.
Results of the methodological quality assessment*
| Fulfilled validity criteria | Unfulfilled validity criteria | Incomplete information for validity assessment | Internal validity score | Methodological quality | ||||
|---|---|---|---|---|---|---|---|---|
| Study | Selection bias (1,2,3) | Performance bias (5) | Attrition bias (6,8) | Detection bias (4,7) | ||||
| Lawlor et al. [ | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
| Chimento et al. [ | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
| Ogonda et al. [ | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
| Kim [ | 1,3 | 5 | 6 | 4,7 | 2,8 | - | 6 | High |
| Bennett et al. [ | 3 | 5 | 6 | 4,7 | 8 | 1,2 | 5 | Medium |
| Chung et al. [ | 3 | 5 | 6 | 4,7 | 1,2,8 | - | 5 | Medium |
| Khan et al. [ | 3 | 5 | 6 | 4,7 | 1,2,8 | - | 5 | Medium |
| Dorr et al. [ | 3 | 5 | 6 | 4,7 | 8 | 1,2 | 5 | Medium |
| Ciminiello et al. [ | 3 | 5 | 6 | 7 | 1,2,4,8 | - | 4 | Medium |
| Dutka et al. [ | 3 | - | 6 | 4,7 | 1,2,8 | 5 | 4 | Medium |
| Hart et al. [ | 3 | - | 6 | 4,7 | 8 | 1,2,5 | 4 | Medium |
| Mazoochian et al. [ | 3 | 5 | - | 4,7 | 8 | 1,2,6 | 4 | Medium |
| Rittmeister & Peters [ | 3 | 5 | 6 | 7 | 1,2,4,8 | - | 4 | Medium |
| Speranza et al. [ | 3 | 5 | 6 | 7 | 4,8 | 1,2 | 4 | Medium |
| DiGioia et al. [ | 3 | 5 | - | 4,7 | 1,2,8 | 6 | 4 | Medium |
| De Beer et al. [ | 3 | - | 6 | 7 | 1,2,4,8 | 5 | 3 | Medium |
| Levine et al. [ | 3 | - | 6 | 7 | 1,2,4,5,8 | - | 3 | Medium |
| Nakamura et al. [ | 3 | - | 6 | 7 | 1,2,4,5,8 | - | 3 | Medium |
| Leenders et al. [ | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
| Parratte & Argenson [ | 1,2,3 | 5 | 6 | 4,7 | 8 | - | 7 | High |
| Kalteis et al. [ | 1,3 | 5 | 6 | 4,7 | 8 | 2 | 6 | High |
| Kalteis et al. [ | 1,3 | 5 | 6 | 7 | 8 | 2,4 | 5 | Medium |
| Sugano et al. [ | 3 | 5 | 6 | 4,7 | 1,2,8 | - | 5 | Medium |
| Najarian et al. [ | 3 | 5 | 6 | 7 | 1,2,8 | 4 | 4 | Medium |
| Wixson & MacDonald [ | 3 | 5 | 6 | 7 | 1,2,8 | 4 | 4 | Medium |
* Methodological quality criteria are presented in Table 1.
Results of perioperative outcome measures*
| Operative time | Intraoperative blood loss | Length of Stay | |||
|---|---|---|---|---|---|
| Study | Methodological quality | No. of patients | SMD (95% CI) | SMD (95% CI) | SMD (95% CI) |
| Chimento et al. [ | High | 60 | 0.03 (-0.48, 0.54) | -0.74 (-1.26, -0.21) | NE (NS) |
| Ogonda et al. [ | High | 219 | -0.49 (-0.76, -0.22) | -0.29 (-0.56, -0.03) | NE (NS) |
| Kim [ | High | 140 | NE (S, decrease) | NE (NS) | NR |
| Chung et al. [ | Medium | 120 | -0.42 (-0.79, -0.06) | -1.18 (-1.56, -0.79) | -0.73 (-1.10, -0.36) |
| Khan et al. [ | Medium | 200 | -0.01 (-0.29, 0.26) | -0.84 (-1.13. -0.55) | NR |
| Dorr et al. [ | Medium | 60 | -0.32 (-0.83, 0.19) | -0.41 (-0.92, 0.10) | -0.53 (-1.03, -0.03) |
| Ciminiello et al. [ | Medium | 120 | NE (NS) | NE (NS) | NE (NS) |
| Dutka et al. [ | Medium | 120 | -0.88 (-1.25, -0.50) | -1.40 (-1.80, -1.00) | NE (NS) |
| Hart et al. [ | Medium | 120 | NE (NS) | NR | NR |
| Mazoochian et al. [ | Medium | 52 | NE (S, decrease) | NE (S, decrease) | NR |
| Rittmeister & Peters [ | Medium | 152 | NE (NS) | NE (NS) | NR |
| Speranza et al. [ | Medium | 100 | NE (NS) | NE (S, decrease) | NE (NS) |
| DiGioia et al. [ | Medium | 70 | NE (NS) | NR | NE (NS) |
| De Beer et al. [ | Medium | 60 | NE (NS) | -0.77 (-1.30, -0.25) | NE (NS) |
| Levine et al. [ | Medium | 201 | NE (S, decrease) | NE (NS) | NE (S, decrease) |
| Nakamura et al. [ | Medium | 92 | -0.85 (-1.28, -0.42) | -0.42 (-0.84, -0.01) | NR |
| Kalteis et al. [ | High | 60 | NE (S, increase) | NR | NR |
| Kalteis et al. [ | High | 60 | NE (NS) | NR | NR |
| Kalteis et al. [ | Medium | 45 | 0.45 (-0.14, 1.04) | NR | NR |
| Sugano et al. [ | Medium | 180 | NE (S, increase) | NE (NS) | NR |
| Najarian et al. [ | Medium | 100 | NE (S, increase) | NE (S, decrease) | NR |
SMD = standardized mean difference; 95% CI = 95% confidence interval; NE = SMD not estimable; S = reported differences between groups were significant; NS = reported differences between groups were not significant; NR = outcome measure not reported.
* A negative SMD with 95% CI indicates a decrease in operative time, intraoperative blood loss and length of stay in favor of the study group.
Operative complications and acetabular outliers*
| No. of complications | No. of outliers | ||||||
|---|---|---|---|---|---|---|---|
| Study | Methodological quality | Study group | Control group | OR (95% CI) | Study group | Control group | OR (95% CI) |
| Lawlor et al. [ | High | 3/109 | 4/110 | 0.75 (0.16, 3.43) | NR | ||
| Chimento et al. [ | High | 3/28 | 2/32 | 1.80 (0.28, 11.64) | 0 | 0 | - |
| Ogonda et al. [ | High | 3/109 | 6/110 | 0.75 (0.16, 3.43) | 16/105 | 19/109 | 0.85 (0.41, 1.76) |
| Kim [ | High | 3/70 | 2/70 | 1.52 (0.25, 9.40) | 13/70 | 11/70 | 1.22 (0.51, 2.95) |
| Chung et al. [ | Medium | 3/57 | 5/55 | 0.58 (0.13, 2.54) | 0 | 0 | - |
| Khan et al. [ | Medium | 15/100 | 21/100 | 0.66 (0.32, 1.38) | 3/100 | 3/100 | 1.00 (0.20, 5.08) |
| Dorr et al. [ | Medium | 2/30 | 3/30 | 0.64 (0.10, 4.15) | 0 | 0 | - |
| Ciminiello et al. [ | Medium | 0 | 0 | - | 0 | 0 | - |
| Dutka et al. [ | Medium | 1/60 | 1/60 | 1.00 (0.06, 16.37) | 0 | 0 | - |
| Hart et al. [ | Medium | 1/60 | 1/60 | 1.00 (0.06, 16.37) | 0 | 0 | - |
| Mazoochian et al. [ | Medium | 4/26 | 3/26 | 1.39 (0.28, 6.95) | NR | ||
| Rittmeister & Peters [ | Medium | 7/76 | 6/76 | 1.18 (0.38, 3.70) | NR | ||
| Speranza et al. [ | Medium | 3/46 | 0/54 | 8.77 (0.44, 174.38) | 1/46 | 3/54 | 0.38 (0.04, 3.76) |
| DiGioia et al. [ | Medium | 0 | 0 | - | 0 | 0 | - |
| De Beer et al. [ | Medium | 1/30 | 2/30 | 0.48 (0.04, 5.63) | 0 | 0 | - |
| Levine et al. [ | Medium | 14/126 | 13/75 | 0.60 (0.26, 1.35) | NR | ||
| Nakamura et al. [ | Medium | 1/50 | 2/42 | 0.41 (0.04, 4.67) | 4/50 | 5/42 | 0.64 (0.16, 2.57) |
| Leenders et al. [ | High | NR | 7/50 | 14/50 | 0.42 (0.15, 1.15) | ||
| Parratte & Argenson [ | High | 0 | 0 | - | 6/30 | 17/30 | 0.19 (0.06, 0.60) |
| Kalteis et al. [ | High | 0/30 | 1/30 | 0.32 (0.01, 8.24) | 5/30 | 16/30 | 0.17 (0.05, 0.58) |
| Kalteis et al. [ | High | 0/30 | 1/30 | 0.32 (0.01, 8.24) | 2/30 | 16/30 | 0.06 (0.01, 0.31) |
| Kalteis et al. [ | Medium | 0 | 0 | - | 2/23 | 11/22 | 0.10 (0.02, 0.51) |
| Sugano et al. [ | Medium | 0/60 | 7/120 | 0.13 (0.01, 2.23) | 0/59 | 31/111 | 0.02 (0.00, 0.36) |
| Najarian et al. [ | Medium | 2/47 | 2/53 | 1.13 (0.15, 8.38) | 6/47 | 18/53 | 0.28 (0.10, 0.80) |
| Wixson & MacDonald [ | Medium | 2/82 | 1/50 | 1.23 (0.11, 13.87) | 17/82 | 18/50 | 0.46 (0.21, 1.02) |
No. = number; OR = Odds ratio; 95% CI = 95% confidence interval; NR = outcome measure not reported. † Articles report on the same study population.
* An OR below 1 with 95% CI indicates lower odds for complications and outliers in favor of the study group.
Results of outcome measures to evaluate physical functioning after MIS THA*
| Follow-up | |||||
|---|---|---|---|---|---|
| Study | Methodological quality | 6 weeks | 3 months | 6 months | 1 year |
| Ogonda et al. [ | High | 0.08 (-0.18, 0.35) | NR | NR | NR |
| Dorr et al. [ | Medium | NE (NS) | NR | NE (NS) | NR |
| Ciminiello et al. [ | Medium | 0.26 (-0.10, 0.62) | NR | NR | NR |
| Dutka et al. [ | Medium | NE (S) a | NE (NS) | NE (NS) | NR |
| Speranza et al. [ | Medium | NR | NE (NS) | NE (NS) | NR |
| Hart et al. [ | Medium | NR | NE (S) a | NE (NS) | NE (NS) |
| Mazoochian et al. [ | Medium | NE (NS) | NE (S) a | NR | NR |
| DiGioia et al. [ | Medium | NR | NE (S) a | NE (S) a | NE (NS) a |
| De Beer et al. [ | Medium | 0.40 (-0.11, 0.91) | NR | NR | NR |
| Nakamura et al. [ | Medium | NR | NR | NE (NS) | NR |
| Ogonda et al. [ | High | 0.03 (-0.23, 0.30) | NR | NR | NR |
| Ogonda et al. [ | High | 0.13 (-0.13, 0.40) | NR | NR | NR |
| Ogonda et al. [ | High | 0.01 (-0.26, 0.27) | NR | NR | NR |
| Khan et al. [ | Medium | NR | NE (S) a | NR | NE (S) a |
| Khan et al. [ | Medium | NR | NE (NS) | NR | NR |
| Mazoochian et al. [ | Medium | NE (S) a | NE (S) a | NR | NR |
| Speranza et al. [ | Medium | NR | NE (NS) | NE (NS) | NR |
| De Beer et al. [ | Medium | 0.24 (-0.27, 0.74) | NR | NR | NR |
| Lawlor et al. [ | High | -0.10 (-0.37, 0.16) | NR | NR | NR |
| Ogonda et al. [ | High | 0.19 (-0.07, 0.46) | NR | NR | NR |
| Bennet et al. [ | Medium | NE (NS) | NR | NR | NR |
| Dorr et al. [ | Medium | NE (NS) | NE (NS) | NR | NR |
Scores are reported as SMD (95%CI). NE = SMD not estimable; S = reported differences between groups were significant; NS = reported differences between groups were not significant; NR = outcome measure not reported. * scores on the HHS; † scores on the Merle d'Aubigné Hip score; ‡ scores on the WOMAC; § scores on the OHS; ** scores on the physical component of the SF-36; †† scores on the physical component of the SF-12. a Improvement in score. b Gait velocity is used as outcome measure for gait analysis.
* A positive SMD with 95% CI indicates better physical functioning in favor of the study group.
Results of outcome measures to evaluate pain after THA.
| Follow-up | |||||
|---|---|---|---|---|---|
| Study | Methodological quality | 6 weeks | 3 months | 6 months | 1 year |
| Kim[ | High | NE (NS) | NE (NS) | NR | NE (NS) |
| Dutka et al. [ | Medium | -0.51 (-0.87, -0.15) | -0.13 (-0.49, 0.23) | -0.31 (-0.67, 0.05) | NR |
| Hart et al. [ | Medium | NE (NS) | NR | NE (NS) | NE (NS) |
| DiGioia et al. [ | Medium | NR | NE (NS) | NE (NS) | NE (NS) |
| Nakamura et al. [ | Medium | NR | NR | NE (NS) | NR |
Scores are reported as SMD (95%CI). NE = SMD not estimable; S = reported differences between groups were significant; NS = reported differences between groups were not significant; NR = outcome measure not reported. * score on a VAS for pain; † score on the pain subscale of the Merle d'Aubigné Hip score; ‡ score on the pain subscale of the HHS.